18:36 , Mar 24, 2017 |  BioCentury  |  Strategy

Connecting in Kyoto

While Novo Nordisk A/S is banking on its clinical pipeline and late-stage M&A to rejuvenate its P&L, a recent “innovation summit” with Japanese researchers shows the company hasn’t given up hunting for academic science. Novo held...
08:00 , Mar 3, 2014 |  BioCentury  |  Emerging Company Profile

Zebra Biologics: Antibody express

Zebra Biologics Inc. is using technology licensed from The Scripps Research Institute that accelerates the functional characterization of antibodies by pooling Abs that bind to a given target into a single cell-based reporter system. The...
08:00 , Dec 5, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes; obesity Adiponectin (ADIPOQ); adiponectin receptor 1 (ADIPOR1); ADIPOR2 Mouse studies suggest a dual ADIPOR1 and...
07:00 , Jun 19, 2006 |  BioCentury  |  Product Development

Showcasing new diabetes targets

While much of the attention at last week’s American Diabetes Association meeting was focused on late-stage products targeting DPP-4 and GLP-1, companies also presented early data on new targets, including adiponectin receptor 2 and eukaryotic...